NCT07821515 Does Paracetamol Influence the Release of Gut Hormones, Glucose Absorption and Glycemia?
| NCT ID | NCT07821515 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Copenhagen |
| Condition | Healthy Young Adults |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12 participants in total. It began in 2026-06-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aim is to determine whether acute inhibition of endogenous prostaglandin synthesis by paracetamol affects the release of gut hormones, glucose absorption and glycemia in healthy young individuals
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Nondiabetic fasting plasma glucose (\< 7.0 mmol/L) at time of inclusion * BMI of 20-25 * Written informed consent Exclusion Criteria: * Haemoglobin \< 7.9 mmol/L * Pregnancy or breastfeeding * Significant gastrointestinal symptoms (e.g. dyspepsia, postprandial pain) * Use of medication that cannot be paused for 12 hours or any drug that affects gastric emptying, small intestinal motility, glucose absorption. * Use of paracetamol, NSAID, aspirin or similar within the previous week. * Evidence of drug abuse, consumption of tobacco in any form or daily consumption of more than 20g alcohol * History of gastrointestinal disease, including significant upper or lower gastrointestinal symptoms, pancreatitis, or previous gastrointestinal surgery including cholecystectomy (but not uncomplicated appendicectomy) * Participation in other research studies within the previous 3 months * Inability to give informed consent * Intolerance to any of the components of paracetamol and the meals used for the study
Contact & Investigator
Simon Veedfald, MD, PhD
PRINCIPAL INVESTIGATOR
Department of BIomedical Scienes, University Copenhagen
Frequently Asked Questions
Who can join the NCT07821515 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Young Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07821515 currently recruiting?
Yes, NCT07821515 is actively recruiting participants. Contact the research team at veedfald@sund.ku.dk for enrollment information.
Where is the NCT07821515 trial being conducted?
This trial is being conducted at Copenhagen, Denmark, Hvidovre, Denmark.
Who is sponsoring the NCT07821515 clinical trial?
NCT07821515 is sponsored by University of Copenhagen. The principal investigator is Simon Veedfald, MD, PhD at Department of BIomedical Scienes, University Copenhagen. The trial plans to enroll 12 participants.